Uchida K, Kigoshi T, Nakano S, Ishii T, Kitazawa M, Morimoto S
Department of Internal Medicine, Kanazawa Medical University, Ishikawa, Japan.
Clin Ther. 1995 May-Jun;17(3):460-6. doi: 10.1016/0149-2918(95)80111-1.
The effects of treatment with epalrestat, an aldose reductase inhibitor, on peripheral neuropathy were studied in 45 patients with non-insulin-dependent diabetes mellitus (NIDDM). Epalrestat 150 mg three times daily was given for 24 weeks. Subjective symptoms, such as spontaneous pain in the lower extremities and numbness and hypoesthesia of the extremities or trunk, were significantly (P < 0.001) relieved after 12 and 24 weeks of epalrestat treatment. Vibratory perception thresholds, as measured by using a tuning fork (C-128) and a vibrometer, were improved after 24 weeks of treatment. Furthermore, there were no adverse effects on glucose or lipid metabolism during treatment. These results suggest that long-term (24-week) epalrestat therapy can be used effectively to treat peripheral neuropathy in NIDDM patients without affecting glucose or lipid metabolism.
对45例非胰岛素依赖型糖尿病（NIDDM）患者研究了醛糖还原酶抑制剂依帕司他治疗周围神经病变的效果。给予依帕司他150mg，每日3次，共治疗24周。依帕司他治疗12周和24周后，下肢自发痛、肢体或躯干麻木及感觉减退等主观症状明显减轻（P<0.001）。使用音叉（C-128）和振动计测量的振动觉阈值在治疗24周后得到改善。此外，治疗期间对糖代谢或脂代谢无不良影响。这些结果表明，长期（24周）依帕司他治疗可有效用于治疗NIDDM患者的周围神经病变，且不影响糖代谢或脂代谢。
